A major breakthrough in cystic fibrosis treatment is coming courtesy of Beximco, a Bangladeshi pharmaceutical company. They’re releasing a generic version of the costly ETI drug, originally priced between $300,000 and $370,000 annually. With Beximco’s version costing just $6,750 a year for adults and around $2,000 for children, the financial landscape for countless families is about to shift dramatically.
Cystic fibrosis can turn life into a daily struggle, as the disease results in a dangerous buildup of mucus in the lungs. The soaring costs of treatment have made access to this critical medication nearly impossible for many families. Fortunately, this affordable option not only allows for better access to the medication but also provides newfound hope for patients and their loved ones. It’s a classic case of how a little competition can make a world of difference—if only the rest of the pharma industry would take note!
How do you feel about the cost of essential medications? Could this be the start of a more affordable era for patients?
About the Author
Local Lawton
Local Lawton is a contributor to LocalBeat, covering local news and community stories.
